Journal article
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
Abstract
Two international multicentre randomised controlled trials of drotrecogin alfa (activated) (DrotAA), the Recombinant Human Activated Protein C Worldwide Evaluation of Severe Sepsis (PROWESS) and Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) trials, have produced inconsistent results. When 28-day mortality data from these trials for patients with severe sepsis and at high risk of death are pooled using a …
Authors
Friedrich JO; Adhikari NK; Meade MO
Journal
Critical Care, Vol. 10, No. 3,
Publisher
Springer Nature
Publication Date
2006
DOI
10.1186/cc4947
ISSN
1364-8535